Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Hanson

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
Clinical Breast Cancer|October 11, 2015
A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast CancerMichael B Sawyer, Edith Pituskin, Sambasivarao Damaraju, et al.
Gastroenterology|July 3, 2018
Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative ColitisHans Herfarth, Edward L Barnes, John F Valentine, et al.
Blood|May 5, 2023
Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samplesJasneet Kaur Khalsa, Justin Cha, Filippo Utro, et al.
Nature Communications|June 3, 2020
Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patientsChek Meng Poh, Guillaume Carissimo, Bei Wang, et al.
Biorxiv : the Preprint Server for Biology|July 24, 2020
Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralizationBei Wang, Daniel Asarnow, Wen-Hsin Lee, et al.
Crohn'S & Colitis 360|May 9, 2024
Clinical Decision Making in Inflammatory Bowel Disease Mimics: Practice Management from Inflammatory Bowel Disease LIVEHannah W Fiske, Christopher Ward, Samir A Shah, et al.
Cell|May 11, 2021
Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytiaDaniel Asarnow, Bei Wang, Wen-Hsin Lee, et al.
Plos One|June 23, 2021
The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibodyConrad E Z Chan, Shirley G K Seah, De Hoe Chye, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Clinical Breast Cancer|October 11, 2015
A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast CancerMichael B Sawyer, Edith Pituskin, Sambasivarao Damaraju, et al.
Gastroenterology|July 3, 2018
Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative ColitisHans Herfarth, Edward L Barnes, John F Valentine, et al.
Blood|May 5, 2023
Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samplesJasneet Kaur Khalsa, Justin Cha, Filippo Utro, et al.
Nature Communications|June 3, 2020
Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patientsChek Meng Poh, Guillaume Carissimo, Bei Wang, et al.
Biorxiv : the Preprint Server for Biology|July 24, 2020
Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralizationBei Wang, Daniel Asarnow, Wen-Hsin Lee, et al.
Crohn'S & Colitis 360|May 9, 2024
Clinical Decision Making in Inflammatory Bowel Disease Mimics: Practice Management from Inflammatory Bowel Disease LIVEHannah W Fiske, Christopher Ward, Samir A Shah, et al.
Cell|May 11, 2021
Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytiaDaniel Asarnow, Bei Wang, Wen-Hsin Lee, et al.
Plos One|June 23, 2021
The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibodyConrad E Z Chan, Shirley G K Seah, De Hoe Chye, et al.
Pageof 10